Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9528217 | 0.92 | L3MBTL1 (0.70) | L3MBTL1RAB9ASMN1; SMN2MAPTMGLL | |
| SCHEMBL11653014 | 0.89 | L3MBTL1 (0.86) | L3MBTL1RAB9ASMN1; SMN2MAPTTAAR1 | |
| SCHEMBL706218 | 0.89 | L3MBTL1 (0.55) | L3MBTL1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL24375975 | 0.85 | L3MBTL1 (0.95) | L3MBTL1RAB9ASMN1; SMN2MAPTTAAR1 | |
| SCHEMBL21186859 | 0.85 | L3MBTL1 (0.95) | L3MBTL1RAB9ASMN1; SMN2MAPTTAAR1 | |
| SCHEMBL88597 | 0.85 | L3MBTL1 (0.95) | L3MBTL1RAB9ASMN1; SMN2MAPTTAAR1 | |
| Hydrochloric Acid SCHEMBL8746161 | 0.83 | L3MBTL1 (1.00) | L3MBTL1RAB9ASMN1; SMN2MAPTTAAR1 | |
| SCHEMBL819106 | 0.82 | L3MBTL1 (0.80) | L3MBTL1RAB9ASMN1; SMN2MAPTTAAR1 | |
| SCHEMBL3910280 | 0.82 | L3MBTL1 (0.73) | L3MBTL1RAB9ASMN1; SMN2MAPTTAAR1 | |
| SCHEMBL24641654 | 0.82 | L3MBTL1 (0.73) | L3MBTL1RAB9ASMN1; SMN2MAPTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| EP-1553075-B1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8124645-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-7820682-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| EP-0573548-A1 | NEUROPROTECTANT AGENTS. | AMERICAN HOME PROD (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1992014813-A1 | NEUROPROTECTANT AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | L3MBTL1 1960/4885RAB9A 3477/4885SMN1; SMN2 92/4885 |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | L3MBTL1 1960/4885RAB9A 3477/4885SMN1; SMN2 92/4885 |
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | L3MBTL1 194/4885RAB9A 3183/4885SMN1; SMN2 3745/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | L3MBTL1 3386/4885RAB9A 975/4885SMN1; SMN2 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.